The Biomedical Advanced Research and Development Authority (BARDA), a unique part of the U.S. Department of Health and Human Services, partners with biotechnology firms large and small to develop and make available medical countermeasures such as vaccines, therapeutics, and diagnostics to meet the threat of chemical, biological, radiological agents, emerging infectious diseases, and pandemic influenza.  In fiscal year 2018, BARDA invested $1.4B in the advanced development and acquisition of products to address an array of threats, from Zika to Ebola. Last year, BARDA launched the Division of Research, Innovation, and Ventures (DRIVe) to accelerate the development and availability of transformative technologies and approaches to health security “threats”.Â
Â
Rick Bright, PhD, Director of BARDA, will be in attendance to provide an overview of BARDA’s unique approach to public-private partnerships. Â
BARDA is seeking new partners in the following areas:Â
   Early and/or pre-symptomatic disease detectionÂ
   Transformative production technologiesÂ
   Diagnostics for use outside of medical settingsÂ
   New approaches respiratory protectionÂ
   Novel vaccine and drug administrationÂ
   Special Interests:Â
        New approaches to diagnose, treat and prevent influenza infectionÂ
        Approaches to address the threat of antimicrobial resistant
        bacterial infectionsÂ
        Approaches to address sepsis Â
After the presentation we will have a networking reception light food and beverages included. Rick will meet 1-on-1 with pre-selected companies prior to presentation. To be considered for a 1-on-1 meeting, please apply here. Applications due by Sep. 5th.Â
Deputy Assistant Secretary for Preparedness and Response and Director, Biomedical Advanced Research Authority (BARDA), U.S. Department of Health and Human Services
Dr. Bright oversees development and procurement of medical countermeasures against an array of threats to national security and the public’s health, including chemical, biological, radiological, nuclear threats and pandemic influenza, and emerging infectious diseases. Dr. Bright has extensive experience in the biotechnology industry where he served in senior leadership and executive management roles as well as senior scientific leadership positions in non-governmental organizations where he championed innovative vaccine development and international vaccine manufacturing capacity expansion in developing countries. Dr. Bright serves as an international subject matter expert in biodefense, vaccine, drug and diagnostics development and serves as an advisor to the World Health Organization and the United States Department of Defense.
BARDA is responsible for developing and procuring technologies and countermeasures to protect the nation against natural and intentional threats. They have delivered solutions to protect our country and the world from threats like anthrax, smallpox, Ebola, pandemic influenza, and many others. Since it was established in 2006, there have been 42 FDA approvals, licensures, and clearances for BARDA-supported products addressing a wide range of chemical, biological, radiological, and nuclear threats; pandemic influenza; and emerging infectious diseases.Â
BARDA's mission is accomplished through successful public-private partnerships with industry to share risk, improve efficiency, and accelerate development all while sustaining a marketplace that guarantees continued access to the vaccines, therapeutics, diagnostics, and other medical products that are vital to our national health security.Â
The views expressed during this event, including during any associated networking and/or individual meetings by anyone other than an employee of Johnson & Johnson Innovation LLC, its parent company or any affiliate companies (herein after referred to as “JJI”) are those of the speakers or experts alone, and such experts or speakers are solely responsible for the information and opinions expressed by them.  By hosting this event, the presentations [and the associated networking and/or individual meetings], JJI does not endorse the views of the speakers, experts or the attendees, and JJI makes no warranties, express or implied, as to the content, the views, advice or the information presented.
